Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).

NCT02142205 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02142205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02142205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2012
Completion date
December 31, 2013
Enrollment
100 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis